Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
57 hedge funds and large institutions have $48.4M invested in Sio Gene Therapies Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 15 closing their positions.
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
61% more capital invested
Capital invested by funds: $30M → $48.4M (+$18.4M)
7% less funds holding
Funds holding: 61 → 57 (-4)
13% less call options, than puts
Call options by funds: $434K | Put options by funds: $501K
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$7.09M |
| 2 |
JG
Jefferies Group
New York
|
+$3.14M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.11M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.81M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.51M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.85M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$577K |
| 4 |
HP
Hound Partners
New York
|
-$398K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$340K |
SIOX Hedge Fund Activity: Q1 2019 in Review
57 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q1 2019, worth a combined $48.4M — up 61% from $30M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SIOX and 11 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 23 added.
The largest buyer was CVI Holdings, adding an estimated $7.09M. The largest seller was Deerfield Management, cutting an estimated $7.51M.
- 57 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q1 2019, down from 61 in Q4 2018.
- Funds reported $48.4M of Sio Gene Therapies Inc. Common Stock stock for Q1 2019, up 61% quarter-over-quarter.
- 11 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q1 2019 and 15 closed out, a net change of -4 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q1 2019 was CVI Holdings, an estimated $7.09M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q1 2019 was Deerfield Management, an estimated $7.51M sold.
Based on aggregated 13F filings for Q1 2019.